153 related articles for article (PubMed ID: 37233443)
1. In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma.
Hu A; Tang K; Liu J; Han X; Chen Q
Medicine (Baltimore); 2023 May; 102(21):e33755. PubMed ID: 37233443
[TBL] [Abstract][Full Text] [Related]
2. Role of Prognostic Marker
Wang WH; Ma CG; Cui YS; Bai BY; Sheng ZM; Liu J; Li A; Zhang BG
Biomed Environ Sci; 2023 Sep; 36(9):862-868. PubMed ID: 37803898
[TBL] [Abstract][Full Text] [Related]
3. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
4. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
5. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
6. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
Wei S; Xing J; Lu K; Wang K; Yu W
Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
8. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
9. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
[TBL] [Abstract][Full Text] [Related]
10. NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden.
Li Z; Zheng Y; Wu Z; Zhuo T; Zhu Y; Dai L; Wang Y; Chen M
Medicine (Baltimore); 2023 Jan; 102(3):e32686. PubMed ID: 36701707
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
12. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
13. Elevated ADAR expression is significantly linked to shorter overall survival and immune infiltration in patients with lung adenocarcinoma.
Hu S; Wang F; Yang J; Xu X
Math Biosci Eng; 2023 Sep; 20(10):18063-18082. PubMed ID: 38052548
[TBL] [Abstract][Full Text] [Related]
14. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
15. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
[TBL] [Abstract][Full Text] [Related]
16. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
[TBL] [Abstract][Full Text] [Related]
17. A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining.
Liu J; Hou S; Wang J; Chai Z; Hong X; Zhao T; Sun Z; Bai L; Gao H; Gao J; Chen G
Oxid Med Cell Longev; 2020; 2020():8847226. PubMed ID: 33414898
[TBL] [Abstract][Full Text] [Related]
18. TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.
Jing Y; Mao Z; Zhu J; Ma X; Liu H; Chen F
Int Immunopharmacol; 2023 Sep; 122():110605. PubMed ID: 37451021
[TBL] [Abstract][Full Text] [Related]
19. ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis.
Chen B; Shen K; Zhang T; Gao WC
Medicine (Baltimore); 2023 Sep; 102(36):e35013. PubMed ID: 37682172
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
Zhang H; Lin J; Yahaya BH
J Cancer Res Clin Oncol; 2024 Jan; 150(2):44. PubMed ID: 38281298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
